DSIP

A nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from the cerebral venous blood of rabbits during electrically induced sleep by Schoenenberger and Monnier at the University of Basel (characterized in PNAS, 1977). Despite nearly five decades of research, no specific receptor, gene, or precursor protein has been identified for DSIP.

Multiple mechanisms have been proposed including GABAergic modulation, HPA axis suppression, alpha-1-adrenergic modulation of pineal melatonin synthesis, opioid receptor interaction, and enhanced mitochondrial oxidative phosphorylation. DSIP freely crosses the blood-brain barrier and is unusually absorbed intact from the gut. Only the alpha-aspartyl form at position 5 is biologically active.

Limited human pilot studies exist for pain and withdrawal, but no completed randomized clinical trials have been published.

DSIP was characterized via cross-circulation experiments between sleeping and awake rabbits (Schoenenberger & Monnier, PNAS 1977), showing a 35% increase in delta EEG activity. Despite decades of study, the Kovalzon & Strekalova 2006 review (J Neurochem) concluded the sleep-factor hypothesis remains poorly documented and no receptor or gene has been identified.

Research has extended to opioid and alcohol withdrawal, pain modulation via supraspinal opioid pathways, stroke recovery (intranasal in rat MCAO models), depression (altered plasma/CSF levels), and cancer biology (2.6-fold decrease in spontaneous tumor incidence in mice, 24.1% increase in maximum lifespan). Small human pilot studies exist for chronic pain and insomnia, but no peer-reviewed randomized controlled trials have been completed as of March 2026.

Community dosing protocols are based on limited clinical pilot data and anecdotal experience.